TY - JOUR AU - Curatolo, P. AU - Bombardieri, R. AU - Jozwiak, S. PY - 2008 DA - 2008// TI - Tuberous sclerosis JO - Lancet VL - 372 UR - https://doi.org/10.1016/S0140-6736(08)61279-9 DO - 10.1016/S0140-6736(08)61279-9 ID - Curatolo2008 ER - TY - JOUR AU - Slegtenhorst, M. PY - 1997 DA - 1997// TI - Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34 JO - Science VL - 277 UR - https://doi.org/10.1126/science.277.5327.805 DO - 10.1126/science.277.5327.805 ID - Slegtenhorst1997 ER - TY - STD TI - European Chromosome 16 Tuberous sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305–15. ID - ref3 ER - TY - JOUR AU - Crino, P. B. PY - 2016 DA - 2016// TI - The mTOR signalling cascade: paving new roads to cure neurological disease JO - Nat Rev Neurol VL - 12 UR - https://doi.org/10.1038/nrneurol.2016.81 DO - 10.1038/nrneurol.2016.81 ID - Crino2016 ER - TY - JOUR AU - Tee, A. R. PY - 2002 DA - 2002// TI - Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling JO - Proc Natl Acad Sci U S A VL - 99 UR - https://doi.org/10.1073/pnas.202476899 DO - 10.1073/pnas.202476899 ID - Tee2002 ER - TY - JOUR AU - Rovira, A. PY - 2014 DA - 2014// TI - Recommendations for the radiological diagnosis and follow-up of neuropathological abnormalities associated with tuberous sclerosis complex JO - J Neurooncol VL - 118 UR - https://doi.org/10.1007/s11060-014-1429-y DO - 10.1007/s11060-014-1429-y ID - Rovira2014 ER - TY - JOUR AU - Curatolo, P. PY - 1991 DA - 1991// TI - Neuropsychiatric aspects of tuberous sclerosis JO - Ann N Y Acad Sci VL - 615 UR - https://doi.org/10.1111/j.1749-6632.1991.tb37743.x DO - 10.1111/j.1749-6632.1991.tb37743.x ID - Curatolo1991 ER - TY - JOUR AU - Krueger, D. A. AU - Northrup, H. PY - 2013 DA - 2013// TI - Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference JO - Pediatr Neurol VL - 49 UR - https://doi.org/10.1016/j.pediatrneurol.2013.08.002 DO - 10.1016/j.pediatrneurol.2013.08.002 ID - Krueger2013 ER - TY - JOUR AU - Curatolo, P. AU - Moavero, R. AU - Vries, P. J. PY - 2015 DA - 2015// TI - Neurological and neuropsychiatric aspects of tuberous sclerosis complex JO - Lancet Neurol VL - 14 UR - https://doi.org/10.1016/S1474-4422(15)00069-1 DO - 10.1016/S1474-4422(15)00069-1 ID - Curatolo2015 ER - TY - JOUR AU - Curatolo, P. PY - 2016 DA - 2016// TI - The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions JO - Drugs VL - 16 UR - https://doi.org/10.1007/s40265-016-0552-9 DO - 10.1007/s40265-016-0552-9 ID - Curatolo2016 ER - TY - JOUR AU - Wang, S. AU - Fallah, A. PY - 2014 DA - 2014// TI - Optimal management of seizures associated with tuberous sclerosis complex: current and emerging options JO - Neuropsychiatr Dis Treat VL - 10 ID - Wang2014 ER - TY - JOUR AU - Scheppingen, J. PY - 2016 DA - 2016// TI - Expression of microRNAs miR21, miR146a, and miR155 in tuberous sclerosis complex cortical tubers and their regulation in human astrocytes and SEGA-derived cell cultures JO - Glia VL - 64 ID - Scheppingen2016 ER - TY - JOUR AU - Muhlebner, A. PY - 2016 DA - 2016// TI - Specific pattern of maturation and differentiation in the formation of cortical tubers in tuberous sclerosis omplex (TSC): evidence from layer-specific marker expression JO - J Neurodev Disord VL - 8 UR - https://doi.org/10.1186/s11689-016-9142-0 DO - 10.1186/s11689-016-9142-0 ID - Muhlebner2016 ER - TY - JOUR AU - Fuso, A. PY - 2016 DA - 2016// TI - Promoter-Specific Hypomethylation Correlates with IL-1beta Overexpression in Tuberous Sclerosis Complex (TSC) JO - J Mol Neurosci VL - 59 UR - https://doi.org/10.1007/s12031-016-0750-7 DO - 10.1007/s12031-016-0750-7 ID - Fuso2016 ER - TY - JOUR AU - Muhlebner, A. PY - 2016 DA - 2016// TI - Novel Histopathological Patterns in Cortical Tubers of Epilepsy Surgery Patients with Tuberous Sclerosis Complex JO - PLoS One VL - 11 UR - https://doi.org/10.1371/journal.pone.0157396 DO - 10.1371/journal.pone.0157396 ID - Muhlebner2016 ER - TY - JOUR AU - Cappellano, A. M. PY - 2013 DA - 2013// TI - Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex JO - Childs Nerv Syst VL - 29 UR - https://doi.org/10.1007/s00381-013-2170-0 DO - 10.1007/s00381-013-2170-0 ID - Cappellano2013 ER - TY - JOUR AU - Franz, D. N. PY - 2013 DA - 2013// TI - Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial JO - Lancet VL - 381 UR - https://doi.org/10.1016/S0140-6736(12)61134-9 DO - 10.1016/S0140-6736(12)61134-9 ID - Franz2013 ER - TY - JOUR AU - Bissler, J. J. PY - 2013 DA - 2013// TI - Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial JO - Lancet VL - 381 UR - https://doi.org/10.1016/S0140-6736(12)61767-X DO - 10.1016/S0140-6736(12)61767-X ID - Bissler2013 ER - TY - JOUR AU - Curatolo, P. PY - 2015 DA - 2015// TI - Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy JO - Pediatr Neurol VL - 52 UR - https://doi.org/10.1016/j.pediatrneurol.2014.10.028 DO - 10.1016/j.pediatrneurol.2014.10.028 ID - Curatolo2015 ER - TY - JOUR AU - Krueger, D. A. PY - 2013 DA - 2013// TI - Everolimus treatment of refractory epilepsy in tuberous sclerosis complex JO - Ann Neurol VL - 74 UR - https://doi.org/10.1002/ana.23960 DO - 10.1002/ana.23960 ID - Krueger2013 ER - TY - JOUR AU - Wheless, J. W. PY - 2015 DA - 2015// TI - Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy JO - Epilepsy Behav Case Rep VL - 4 UR - https://doi.org/10.1016/j.ebcr.2015.06.008 DO - 10.1016/j.ebcr.2015.06.008 ID - Wheless2015 ER - TY - JOUR AU - Wiemer-Kruel, A. PY - 2014 DA - 2014// TI - Everolimus for the treatment of subependymal giant cell astrocytoma probably causing seizure aggravation in a child with tuberous sclerosis complex: a case report JO - Neuropediatrics VL - 45 ID - Wiemer-Kruel2014 ER - TY - STD TI - French, JA, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016. ID - ref23 ER - TY - STD TI - Brakemeier S, Bachmann F, and Budde K. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients. Pediatr Nephrol. 2016;1-8. [Epub ahead of print] ID - ref24 ER - TY - JOUR AU - Bissler, J. J. PY - 2008 DA - 2008// TI - Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis JO - N Engl J Med VL - 358 UR - https://doi.org/10.1056/NEJMoa063564 DO - 10.1056/NEJMoa063564 ID - Bissler2008 ER - TY - JOUR AU - Franz, D. N. PY - 2006 DA - 2006// TI - Rapamycin causes regression of astrocytomas in tuberous sclerosis complex JO - Ann Neurol VL - 59 UR - https://doi.org/10.1002/ana.20784 DO - 10.1002/ana.20784 ID - Franz2006 ER - TY - JOUR AU - Sheth, R. A. PY - 2016 DA - 2016// TI - Angiographic and volumetric effects of mammalian target of rapamycin inhibitors on angiomyolipomas in tuberous sclerosis JO - World J Radiol VL - 8 UR - https://doi.org/10.4329/wjr.v8.i3.308 DO - 10.4329/wjr.v8.i3.308 ID - Sheth2016 ER - TY - JOUR AU - Bissler, J. J. PY - 2016 DA - 2016// TI - Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial JO - Nephrol Dial Transplant VL - 31 UR - https://doi.org/10.1093/ndt/gfv249 DO - 10.1093/ndt/gfv249 ID - Bissler2016 ER - TY - JOUR AU - Berg, A. T. PY - 2010 DA - 2010// TI - Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009 JO - Epilepsia VL - 51 UR - https://doi.org/10.1111/j.1528-1167.2010.02522.x DO - 10.1111/j.1528-1167.2010.02522.x ID - Berg2010 ER - TY - JOUR AU - Kwan, P. PY - 2010 DA - 2010// TI - Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies JO - Epilepsia VL - 51 UR - https://doi.org/10.1111/j.1528-1167.2009.02397.x DO - 10.1111/j.1528-1167.2009.02397.x ID - Kwan2010 ER - TY - BOOK PY - 2004 DA - 2004// TI - Common Terminology Criteria for Adverse Events (CTCAE) ID - ref31 ER - TY - JOUR AU - Krueger, D. A. PY - 2013 DA - 2013// TI - Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma JO - Neurology VL - 80 UR - https://doi.org/10.1212/WNL.0b013e3182815428 DO - 10.1212/WNL.0b013e3182815428 ID - Krueger2013 ER - TY - JOUR AU - Krueger, D. A. PY - 2010 DA - 2010// TI - Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1001671 DO - 10.1056/NEJMoa1001671 ID - Krueger2010 ER - TY - JOUR AU - Muncy, J. AU - Butler, I. J. AU - Koenig, M. K. PY - 2009 DA - 2009// TI - Rapamycin reduces seizure frequency in tuberous sclerosis complex JO - J Child Neurol VL - 24 UR - https://doi.org/10.1177/0883073808324535 DO - 10.1177/0883073808324535 ID - Muncy2009 ER - TY - JOUR AU - Perek-Polnik, M. PY - 2012 DA - 2012// TI - Effective everolimus treatment of inoperable, life-threatening subependymal giant cell astrocytoma and intractable epilepsy in a patient with tuberous sclerosis complex JO - Eur J Paediatr Neurol VL - 16 UR - https://doi.org/10.1016/j.ejpn.2011.09.006 DO - 10.1016/j.ejpn.2011.09.006 ID - Perek-Polnik2012 ER - TY - JOUR AU - Moavero, R. PY - 2013 DA - 2013// TI - Is mTOR inhibition a systemic treatment for tuberous sclerosis? JO - Ital J Pediatr VL - 39 UR - https://doi.org/10.1186/1824-7288-39-57 DO - 10.1186/1824-7288-39-57 ID - Moavero2013 ER - TY - JOUR AU - Wiegand, G. PY - 2013 DA - 2013// TI - Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? JO - Eur J Paediatr Neurol VL - 17 UR - https://doi.org/10.1016/j.ejpn.2013.06.002 DO - 10.1016/j.ejpn.2013.06.002 ID - Wiegand2013 ER - TY - JOUR AU - Cardamone, M. PY - 2014 DA - 2014// TI - Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex JO - J Pediatr VL - 164 UR - https://doi.org/10.1016/j.jpeds.2013.12.053 DO - 10.1016/j.jpeds.2013.12.053 ID - Cardamone2014 ER - TY - JOUR AU - Citraro, R. PY - 2016 DA - 2016// TI - mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis JO - Pharmacol Res VL - 107 UR - https://doi.org/10.1016/j.phrs.2016.03.039 DO - 10.1016/j.phrs.2016.03.039 ID - Citraro2016 ER - TY - JOUR AU - Russo, E. PY - 2012 DA - 2012// TI - The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis JO - Mol Neurobiol VL - 46 UR - https://doi.org/10.1007/s12035-012-8314-5 DO - 10.1007/s12035-012-8314-5 ID - Russo2012 ER - TY - JOUR AU - Wong, M. PY - 2013 DA - 2013// TI - A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials JO - Expert Rev Neurother VL - 13 UR - https://doi.org/10.1586/ern.13.48 DO - 10.1586/ern.13.48 ID - Wong2013 ER - TY - JOUR AU - Galanopoulou, A. S. AU - Gorter, J. A. AU - Cepeda, C. PY - 2012 DA - 2012// TI - Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target JO - Epilepsia VL - 53 UR - https://doi.org/10.1111/j.1528-1167.2012.03506.x DO - 10.1111/j.1528-1167.2012.03506.x ID - Galanopoulou2012 ER - TY - JOUR AU - Sadowski, K. AU - Kotulska-Jozwiak, K. AU - Jozwiak, S. PY - 2015 DA - 2015// TI - Role of mTOR inhibitors in epilepsy treatment JO - Pharmacol Rep VL - 67 UR - https://doi.org/10.1016/j.pharep.2014.12.017 DO - 10.1016/j.pharep.2014.12.017 ID - Sadowski2015 ER -